The "Spectacular Breakup" of ImmuneOnco Biopharma
Act decisively when the time comes.
Time：
2026-01-07 18:48
Author：
xieyijun
Retreat and Offense: The Next Phase of the KRAS-Targeted Therapeutics Battle
The competition in the KRAS field has entered a new chapter.
Time：
2026-01-07 08:14
Author：
xieyijun
Unlocking Eli Lilly's Trillion-Dollar Potential: When a Pharma Giant Goes "Tech"
Eli Lilly's CEO Guest Stars on Tech Podcast
Time：
2026-01-06 08:09
Author：
xieyijun
With a $300 Billion Patent Cliff, What Should We Buy?
he flow of M&A funds has been redirected.
Time：
2026-01-05 08:12
Author：
xieyijun
10-Month Sprint: The Battle for Reimbursement of an Innovative Drug
Exclusive Interview with Trinomab
Time：
2026-01-01 20:55
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务